Uso de Rosuvastatina em Esclerose Múltipla
DOI:
https://doi.org/10.34024/rnc.2007.v15.8695Palavras-chave:
Inibidores de hidroximetilglutaril-CoA redutases, Esclerose Múltipla, Terapias em estudoResumo
A terapêutica convencional da esclerose múltipla (EM) compreende o uso de imunossupressores e imunomoduladores. Como as estatinas têm ações antiinflamatórias e imunomoduladoras, elas poderiam constituir uma terapia alternativa para essa doença. Descrevemos neste trabalho o resultado do uso de rosuvastatina por uma paciente de 34 anos, portadora de EM remitente-recorrente. A paciente iniciou tratamento com interferon-beta 1A, porém, após queixas de efeitos adversos, recusou-se a continuar o tratamento. Em 2005, ela iniciou uso de rosuvastatina. Seu EDSS (Expanded Disability Status Scale) era igual a 6,0. Após 6 meses de tratamento, ela apresentava boa evolução no quadro neurológico, passando a deambular distâncias maiores e a praticar exercícios físicos. Seu EDSS baixou para 4,5. O tratamento com estatina é racionalmente promissor na melhoria da qualidade de vida e, provavelmente, no controle da doença.
Downloads
Métricas
Referências
Rose JW, Hill KE, Watt HE, Carlson NG. Inflammatory cell expression of cyclooxigenase 2 in the multiple sclerosis lesion. J Neuroimmunol 2004;149:40-9.
Duarte F, Pittella JEH, Ávila CM, Rosemberg S, Hahn MD, Chimelli L, et al. Sistema nervoso. In: Bogliolo L (ed). Patologia Geral. Rio de Janeiro: Guanabara Koogan, 1994. pp. 723-825.
Goodkin DE, Hauser SL. Esclerose múltipla e outras doenças desmielinizantes. In: Harrison TR (ed). Medicina Interna. Rio de Janeiro: McGraw Hill Interamericana do Brasil, 2001. pp. 2554-62.
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA). Adivisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
Academia Brasileira de Neurologia. Departamento Científico de Neuroimunologia. Guidelines for the treatment of multiple sclerosis with immunomodulatory drugs. Arq Neuropsiquiatr 2005;63:892-5.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005;58:840-6.
Takemoto M, Liao JK. Pleiotropic effects of 3-hyroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arterioscl Thromb Vasc Biol 2001;21:1712-9.
Pahan K, Sheikh FG, Namboorodiri AMS, Singh I. Lovastatin and phenil-acetate inhibit the reduction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J Clin Invest 1997;100:2671-9.
Okazaki H, Nagashima T, Minota S. Immunomodulatory activities of statins. Jap J Clin Immunol 2004;27:357-60.
Raja SG, Dreyfus GD. Statins: much more than just a lipid-lowering therapy. Indian Heart J 2004;56:204-9.
Neuhaus O, Stuve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet Neurology 2004;3:369-71.
Tajouri L, Ferreira L, Ovcaric M, Curtain R, Lea R, Csurhes P, et al. Investigation of a neuronal nitric oxide synthase gene (NOS1) polymorphism in a multiple sclerosis population. J Neurol Sci 2004;218:25-8.
Sena A, Pedrosa R, Morais MG. Therapeutic potential of lovastatin in multiple sclerosis. J. Neurol 2003;250:754-5.
Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-8.
Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-69.
Neuhhaus O, Stuve O, Archelos JJ, Hartung HP. Putative mechanisms of action of statins in multiple sclerosis - comparison to interferon-B and glatiramer acetate. J Neurol Sci 2005;233:173-7.
Wekerle H. Tackling multiple sclerosis. Nature 2002;420:39-40.
Morikawa S, Murakami T, Yamazaki H, Izumi A, Saito Y, Hamakubo T, et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 2005;12:121-31.
Ferdinand KC. Rosuvastatin: a risk-benefit assessment for intensive lipid-lowering. Expert Opin Pharmacother 2005;6:1897-910.
Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, et al. Statins as imunomodulators. Comparison with interferon-β 1b in MS. Neurology 2002;59:990-7.
Polman CH, Killestein J. Statins for the treatment of multiple sclerosis: cautions hope. The Lancet 2004;363:1570.
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2007-09-30
Português
English
Español
